

# FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response...	0.5

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person* Perlysky Dov			2. Issuer Name and Ticker or Trading Symbol ENZO BIOCHEM INC [ENZ]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below)			
(Last) (First) (Middle) C/O ENZO BIOCHEM, INC., 527 MADISON AVENUE			3. Date of Earliest Transaction (Month/Day/Year) 01/14/2019							
(Street) NEW YORK, NY 10022			4. If Amendment, Date Original Filed(Month/Day/Year)				6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person			
(City) (State) (Zip)			<b>Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned</b>							
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	01/14/2019		M <sup>(1)</sup>		9,184	A	\$ 2.70	65,787	D	
Common Stock								523,457	I	See Footnotes <sup>(2)</sup>

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.** SEC 1474 (9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V		Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock option (to acquire common stock)	\$ 2.70	01/14/2019		M		64,286	<sup>(1)</sup>	01/17/2019	Common Stock	64,286	\$ 0	175,346	D	

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Perlysky Dov C/O ENZO BIOCHEM, INC. 527 MADISON AVENUE NEW YORK, NY 10022	X			

## Signatures

/s/ Dov Perlysky	01/18/2019
<small>Signature of Reporting Person</small>	<small>Date</small>

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Represents an exercise of options to acquire 64,286 shares, which, after the company withheld the exercise price for such options, resulted in a delivery of 9,184 shares of common stock to the reporting person.

(2) Includes (i) 33,139 shares owned by Laya Perlysky (Mr. Perlysky's wife) of which Mr. Perlysky disclaims beneficial ownership, (ii) 109,237 shares owned directly by RSD 2012 GRAT, of which Mr. Perlysky is the trustee of which Mr. Perlysky disclaims beneficial ownership, (iii) 45,000 shares owned by Sky Ventures LLC, of which Mr. Perlysky is the manager and of which Dov Perlysky disclaims beneficial ownership, (iv) 325,875 shares owned by Kinder Investments LLP, an entity of which Dov Perlysky is the Managing Member of the General Partner and of which Dov Perlysky disclaims beneficial ownership, (v) 6,981 shares owned by Krovim LLC, an entity of which Dov Perlysky is the Managing Member of the General Partner, and children of Dov Perlysky own a 27.54% interest, and of which Dov Perlysky disclaims beneficial ownership and (vi) 3,225 shares owned by MidAtlantic Capital Lending LLC, an entity of which Dov Perlysky owns 1% and of which Dov Perlysky disclaims beneficial ownership.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.